Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity

Group 1 - Altimmune Inc. (ALT) is preparing for the readout from the IMPACT phase 2b study of pemvidutide, which targets metabolic dysfunction-associated steatohepatitis (MASH) [1] - The analyst rated ALT as a buy in December 2024, based on pemvidutide's profile and the company's valuation [1] - The focus is on trading around significant events such as trial results and NDA/BLA approvals, particularly in the biotech sector [1]